ATE387445T1 - Pyridino 2,3-d pyrimidin-derivate als selektive kdr- und fgfr-inhibitoren - Google Patents

Pyridino 2,3-d pyrimidin-derivate als selektive kdr- und fgfr-inhibitoren

Info

Publication number
ATE387445T1
ATE387445T1 AT03785789T AT03785789T ATE387445T1 AT E387445 T1 ATE387445 T1 AT E387445T1 AT 03785789 T AT03785789 T AT 03785789T AT 03785789 T AT03785789 T AT 03785789T AT E387445 T1 ATE387445 T1 AT E387445T1
Authority
AT
Austria
Prior art keywords
pyridino
pyrimidine derivatives
fgfr inhibitors
kdr
selective
Prior art date
Application number
AT03785789T
Other languages
English (en)
Inventor
Jin-Jun Liu
Kin-Chun Luk
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE387445T1 publication Critical patent/ATE387445T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT03785789T 2002-12-20 2003-12-11 Pyridino 2,3-d pyrimidin-derivate als selektive kdr- und fgfr-inhibitoren ATE387445T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43496902P 2002-12-20 2002-12-20
US51361503P 2003-10-23 2003-10-23

Publications (1)

Publication Number Publication Date
ATE387445T1 true ATE387445T1 (de) 2008-03-15

Family

ID=32685355

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03785789T ATE387445T1 (de) 2002-12-20 2003-12-11 Pyridino 2,3-d pyrimidin-derivate als selektive kdr- und fgfr-inhibitoren

Country Status (15)

Country Link
US (1) US7098332B2 (de)
EP (1) EP1581531B1 (de)
JP (1) JP2006511563A (de)
KR (1) KR100763298B1 (de)
AR (1) AR042532A1 (de)
AT (1) ATE387445T1 (de)
AU (1) AU2003294830B2 (de)
BR (1) BR0317480A (de)
CA (1) CA2508951A1 (de)
DE (1) DE60319430T2 (de)
ES (1) ES2300639T3 (de)
MX (1) MXPA05006437A (de)
PL (1) PL377661A1 (de)
RU (1) RU2345077C2 (de)
WO (1) WO2004056822A1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ATE451104T1 (de) * 2002-07-29 2009-12-15 Rigel Pharmaceuticals Inc Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen
PL1656372T3 (pl) 2003-07-30 2013-08-30 Rigel Pharmaceuticals Inc Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym
EP1749004B1 (de) * 2004-05-04 2007-09-19 Warner-Lambert Company LLC Pyrrolylsubstituierte pyrido[2,3-d]pyrimidin-7-one und derivate davon als therapeutische mittel
US7557207B2 (en) 2004-11-24 2009-07-07 Rigel Pharmaceuticals, Inc. Spiro 2,4-pyrimidinediamine compounds and their uses
JP2008540436A (ja) * 2005-05-03 2008-11-20 ライジェル ファーマシューティカルズ, インコーポレイテッド Jakキナーゼインヒビターおよびそれらの使用
CA2650611A1 (en) * 2006-05-15 2007-11-29 Irm Llc Compositions and methods for fgf receptor kinases inhibitors
JP4718637B2 (ja) 2006-09-15 2011-07-06 ファイザー・プロダクツ・インク ピリド(2,3−d)ピリミジノン化合物およびpi3阻害剤としてのその使用
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
CN107652289B (zh) 2012-06-13 2020-07-21 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
EA036160B1 (ru) * 2013-03-15 2020-10-08 Селджен Кар Ллс Гетероарильные соединения и их применение
AR095464A1 (es) 2013-03-15 2015-10-21 Celgene Avilomics Res Inc Compuestos de heteroarilo y usos de los mismos
KR102350704B1 (ko) 2013-03-15 2022-01-13 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
JP6449244B2 (ja) 2013-04-19 2019-01-09 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Fgfr抑制剤としての二環式複素環
BR112016008276B1 (pt) * 2013-10-25 2021-03-02 Novartis Ag derivados bicíclicos de piridila fundidos ao anel, seus usos e seu intermediário, e composição farmacêutica
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
PL3122358T3 (pl) 2014-03-26 2021-06-14 Astex Therapeutics Ltd. Połączenia inhibitorów fgfr i cmet w leczeniu nowotworu
RU2715893C2 (ru) 2014-03-26 2020-03-04 Астекс Терапьютикс Лтд Комбинации ингибитора fgfr и ингибитора igf1r
JP5925978B1 (ja) 2014-08-18 2016-05-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 単環ピリジン誘導体の塩およびその結晶
JP6585167B2 (ja) * 2014-10-03 2019-10-02 ノバルティス アーゲー Fgfr4阻害剤としての縮環二環式ピリジル誘導体の使用
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
WO2016134320A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9802917B2 (en) * 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
HUE057090T2 (hu) 2015-09-23 2022-04-28 Janssen Pharmaceutica Nv BI-heteroaril-szubsztituált 1,4-benzodiazepinek és alkalmazásuk rák kezelésében
BR112018005637B1 (pt) 2015-09-23 2023-11-28 Janssen Pharmaceutica Nv Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos
AU2016374441B2 (en) * 2015-12-17 2021-10-21 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
EP3589634A4 (de) * 2017-03-03 2020-08-12 Auckland Uniservices Limited Fgfr-kinase-inhibitoren und pharmazeutische verwendungen
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019015593A1 (zh) * 2017-07-19 2019-01-24 江苏奥赛康药业股份有限公司 嘧啶并吡啶酮或者吡啶并吡啶酮类化合物及其应用
MX2020008610A (es) 2018-03-28 2020-09-21 Eisai R&D Man Co Ltd Agente terapeutico para carcinoma hepatocelular.
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
DK3788047T3 (da) 2018-05-04 2024-09-16 Incyte Corp Faste former af en FGFR-inhibitor og fremgangsmåder til fremstilling deraf
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
AR117544A1 (es) 2018-12-27 2021-08-11 Agios Pharmaceuticals Inc Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer
EP3902801A4 (de) * 2018-12-28 2022-12-14 SPV Therapeutics Inc. Cyclinabhängige kinaseinhibitoren
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
JOP20210317A1 (ar) * 2019-05-31 2023-01-30 Servier Lab مثبطات غير متجانسة ثنائية الحلقة لـ mat2a وطرق استخدامها لعلاج السرطان
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021030537A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
PE20221905A1 (es) 2019-10-11 2022-12-23 Incyte Corp Aminas biciclicas como inhibidoras de la cdk2
MX2022004513A (es) 2019-10-14 2022-07-19 Incyte Corp Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Fgfr阻害剤としての三環式複素環
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN112062770A (zh) * 2020-08-21 2020-12-11 台州学院 一种稠环二氢吡啶酮的制备方法
EP4323405A1 (de) 2021-04-12 2024-02-21 Incyte Corporation Kombinationstherapie mit einem fgfr-inhibitor und einem auf nectin-4 abzielenden mittel
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
WO1998024432A2 (en) 1996-12-05 1998-06-11 Sugen, Inc. Use of indolinone compounds as modulators of protein kinases
WO1998033798A2 (en) 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
CZ20011394A3 (cs) 1998-10-23 2001-12-12 F. Hoffmann-La Roche Ag Derivát bicyklických, dusík obsahujících heterocyklických sloučenin, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje
DE60006503T2 (de) 1999-03-16 2004-09-23 Shell Internationale Research Maatschappij B.V. Verfahren zur reinigung von propylenoxid
AR030053A1 (es) 2000-03-02 2003-08-13 Smithkline Beecham Corp 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas
MXPA03000289A (es) 2000-08-04 2003-06-06 Warner Lambert Co Proceso para preparar 2-(4-piridil) amino-6-dialquiloxifenil-pirido (2,3-d) pirimidin-7-onas..
JP2004519422A (ja) 2000-08-04 2004-07-02 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 2−(4−ピリジル)アミノ−6−ジアルコキシフェニルピリド〔2,3−d〕ピリミジン−7−オン
CN1275964C (zh) 2000-08-31 2006-09-20 霍夫曼-拉罗奇有限公司 作为细胞增殖抑制剂的7-氧代吡啶并嘧啶
EP1364212B1 (de) * 2001-03-02 2011-02-02 GPC Biotech AG Drei-hybrid-assaysystem

Also Published As

Publication number Publication date
CA2508951A1 (en) 2004-07-08
AU2003294830B2 (en) 2009-06-11
EP1581531A1 (de) 2005-10-05
US7098332B2 (en) 2006-08-29
ES2300639T3 (es) 2008-06-16
BR0317480A (pt) 2005-11-16
JP2006511563A (ja) 2006-04-06
US20040122029A1 (en) 2004-06-24
AU2003294830A1 (en) 2004-07-14
WO2004056822A1 (en) 2004-07-08
KR20050088202A (ko) 2005-09-02
EP1581531B1 (de) 2008-02-27
PL377661A1 (pl) 2006-02-06
KR100763298B1 (ko) 2007-10-04
DE60319430D1 (de) 2008-04-10
MXPA05006437A (es) 2005-08-19
DE60319430T2 (de) 2009-02-26
AR042532A1 (es) 2005-06-22
RU2345077C2 (ru) 2009-01-27
RU2005122901A (ru) 2006-02-27

Similar Documents

Publication Publication Date Title
ATE387445T1 (de) Pyridino 2,3-d pyrimidin-derivate als selektive kdr- und fgfr-inhibitoren
CY2017015I2 (el) ΕΤΕΡΟΑΡΥΛΟ ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΠΥΡΡΟΛΟ[2,3-b]ΠΥΡΙΔΙΝΕΣ ΚΑΙ ΠΥΡΡΟΛΟ[2,3-b]ΠΥΡΙΜΙΔΙΝΕΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΗΣ JANUS
ATE378049T1 (de) Nicotinamid-derivate als pde4-hemmer
DE60315886D1 (de) Substituierte pyrazin- oder pyridin-derivate als glukokinase-aktivatoren
DE60332396D1 (de) PYRAZOLOi3,4-B PYRIDINVERBINDUNGEN UND IHRE VERWENDUNG ALS PHOSPHODIESTERASE INHIBITOREN
DE60313872D1 (de) Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
DE60333166D1 (de) Pyridin- und pyrimidin-derivate
ATE387446T1 (de) Pyrido(2,3-d)pyrimidin-2,4-diamine als pde-2- inhibitoren
ATE489387T1 (de) Pyridoä2,1-aü-isochinolinderivate als dpp-iv inhibitoren
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
DK1611131T3 (da) Pyrazolopyridin-derivater
ATE441631T1 (de) Phenylpiperidinderivate als serotonin- wiederaufnahmehemmer
ATE446093T1 (de) Substituierte chinazolin-derivate als aurora- kinase inhibitoren
IS7659A (is) COX-2 hamlandi pýridín afleiður
ATE418543T1 (de) Substituierte 1,4-dipiperidin-4-yl- piperazinderivate und deren verwendung als neurokininantagonisten
IS8201A (is) Nikótínamíð afleiður gagnlegar sem PDE4 hindrar
ATE433977T1 (de) Substituierte 8-perfluoro-6,7,8,9- tetrahydropyrimido 1,2-a pyrimidin-4-on-derivate
ATE452892T1 (de) Substituierte 8-perfluoro-6,7,8,9- tetrahydropyrimido-(1,2a) pyrimidin-4-on derivate
ATE309247T1 (de) Heteroaryl substituierte 2-pyridinyl und 2- pyrimidinyl-6,7,8,9-tetrahydropyrimido(1,2- a)pyrimidin-4-onderivate
DE60203529D1 (de) Indolderivate als cox-ii-inhibitoren
NO20055518D0 (no) 5-hydroksyindoler med N-oksidgrupper, anvendelse derav som fosfodiesterase 4-inhibitor
NO20035206L (no) Pyrimidin-derivater anvendelige som selektive COX-2- inhibitorer
IS7366A (is) Nikótínamíð afleiður nytsamlegar sem PDE4 hindrar
GT200300035A (es) Derivados de nicotinamida utiles como inhibidores de pde4

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1581531

Country of ref document: EP

REN Ceased due to non-payment of the annual fee